Achieve Life Sciences Inc

This non-binding advisory proposal asks stockholders to approve the overall compensation paid to the company’s named executive officers as disclosed in the proxy. Management seeks endorsement to validate the Compensation Committee’s pay-for-performance framework, which blends base salary, annual performance-based cash bonuses tied to corporate milestones (e.g., NDA submission and CMC/commercial readiness) and long-term equity incentives including options and performance-based restricted stock units (PSUs) tied to regulatory and corporate transaction outcomes. The Compensation Committee engaged an external advisor (Aon) and set targets near market medians for cash and higher percentile targets for equity to incentivize long-term retention and alignment in a pre-revenue clinical-stage biopharma. Management emphasizes that the say-on-pay vote is advisory and that a negative vote would prompt consideration and possible adjustments by the Board and Compensation Committee. Key contextual factors include the company’s recent leadership transitions, significant equity financings (including a large April 2026 private placement), and material performance milestones (NDA acceptance/approval) embedded in incentive structures. The Board recommends FOR because it believes the program balances retention, recruitment and alignment with shareholder value creation while mitigating excessive short-term risk. From a governance perspective, investors should weigh the degree to which realized pay (including large equity grants and potential acceleration on termination/change-in-control) is sensitive to realized clinical and regulatory outcomes and dilution implications from recent financings. The proposal does not change compensation policy itself but ratifies disclosed decisions and the structure used to incentivize named executives. A sophisticated analyst should consider recent severance and change-in-control provisions, the link between PSUs and regulatory milestones, and the company’s capital plan when evaluating the merits of supporting management’s recommendation.

This proposal asks shareholders to approve a charter amendment doubling the company’s authorized common stock from 150 million to 300 million shares to provide the Board with capacity to satisfy outstanding warrant and pre-funded warrant exercises from recent financings and to preserve flexibility for equity compensation, future capital raises and strategic transactions. Management contends the increase is necessary because after the April 2026 private placement and other reservations there were effectively no unreserved authorized shares available for issuance, and failure to approve would risk breaching obligations to deliver shares upon exercise of warrants and force a special meeting or delay financings. The Board states the amendment is not intended as an anti-takeover measure, but acknowledges that increasing authorized shares can have potential anti-takeover effects by enabling issuance that could dilute hostile bidders — a trade-off shareholders should note. The proposal requires a majority of votes cast and the Board recommends FOR given the operational and financing risks of having exhausted available authorized shares, including the potential inability to issue shares to satisfy exercised warrants which could expose the company to penalties. Analysts should evaluate the dilutive impact of the authorization increase relative to the company’s financing runway, outstanding warrants and equity reserve usage, and consider how management intends to deploy any newly issuable shares. Given the size and timing of recent financings and the specific link to warrant exercise mechanics (including beneficial ownership limitations and exercise timing tied to FDA approval milestones), approval reduces execution risk for the company’s capitalization strategy but may increase long-term dilution risk for existing shareholders.